Asset Management One Co. Ltd. Has $276.65 Million Stock Position in Eli Lilly and Company $LLY

Asset Management One Co. Ltd. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 362,579 shares of the company’s stock after selling 3,654 shares during the quarter. Eli Lilly and Company accounts for approximately 0.8% of Asset Management One Co. Ltd.’s holdings, making the stock its 16th largest holding. Asset Management One Co. Ltd.’s holdings in Eli Lilly and Company were worth $276,648,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Richardson Financial Services Inc. lifted its holdings in shares of Eli Lilly and Company by 16.5% during the 3rd quarter. Richardson Financial Services Inc. now owns 474 shares of the company’s stock valued at $362,000 after purchasing an additional 67 shares in the last quarter. InTrack Investment Management Inc raised its holdings in Eli Lilly and Company by 24.3% during the 3rd quarter. InTrack Investment Management Inc now owns 3,380 shares of the company’s stock worth $2,579,000 after buying an additional 660 shares during the period. Abacus Planning Group Inc. raised its holdings in Eli Lilly and Company by 2.0% during the 3rd quarter. Abacus Planning Group Inc. now owns 2,479 shares of the company’s stock worth $1,892,000 after buying an additional 48 shares during the period. Fifth Third Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 6.6% in the third quarter. Fifth Third Wealth Advisors LLC now owns 18,543 shares of the company’s stock valued at $14,148,000 after buying an additional 1,148 shares in the last quarter. Finally, Penobscot Investment Management Company Inc. boosted its holdings in shares of Eli Lilly and Company by 14.5% in the third quarter. Penobscot Investment Management Company Inc. now owns 11,945 shares of the company’s stock valued at $9,114,000 after buying an additional 1,509 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 3.6%

LLY stock opened at $1,041.78 on Tuesday. The company has a market cap of $984.88 billion, a price-to-earnings ratio of 50.97, a P/E/G ratio of 0.78 and a beta of 0.35. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The business has a 50 day moving average price of $1,017.48 and a two-hundred day moving average price of $853.10. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the firm posted $1.18 EPS. The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is 29.35%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. HSBC reaffirmed a “hold” rating and issued a $1,070.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Scotiabank began coverage on Eli Lilly and Company in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 target price on the stock. Finally, National Bankshares set a $1,286.00 price target on Eli Lilly and Company in a research report on Monday, December 1st. Five research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Buy” and an average price target of $1,161.27.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and commentary cite Lilly’s long‑term growth setup — strong GLP‑1 franchise, a deep obesity pipeline and AI/innovation tailwinds — that support multi‑year revenue upside and justify bullish ratings. 3 Reasons Why Lilly (LLY) Is a Great Growth Stock
• Positive Sentiment: Several investment writeups highlight Lilly as a top stock for 2026 and note the company’s recent revenue trajectory and guidance, which support longer‑term earnings expectations. 3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)
• Neutral Sentiment: Market pieces debate whether now is a buy, hold or sell after a sharp 3‑month gain; these narratives can increase short‑term volatility but don’t change fundamentals immediately. LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?
• Neutral Sentiment: Sector/idea pieces list Lilly among AI‑enabled medtech/biotech names to watch — a thematic positive over time but unlikely to drive intraday moves. Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026
• Negative Sentiment: Market reaction to Novo Nordisk’s U.S. launch of an oral Wegovy pill is the headline pressure point — investors are pricing in faster share loss and margin competition in the obesity/weight‑loss market. Novo Nordisk Stock Jumps as it Battles Eli Lilly for Market Share with $149 Wegovy Pill Launch
• Negative Sentiment: Legal and political risk intensified as Indiana’s Attorney General filed a lawsuit against Lilly over insulin pricing — this raises potential headline/legal costs and regulatory scrutiny. Indiana sues Eli Lilly over insulin prices
• Negative Sentiment: Short‑term selling pressure is also reflected in quick market checks and opinion pieces suggesting profit‑taking or repositioning after Lilly’s strong run and rising valuation multiples. Eli Lilly Stock (LLY) Falls 4% as Rival Novo Nordisk Begins Selling Obesity Pill in U.S.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.